XOMA Corporation (XOMA)
| Market Cap | 241.38M |
| Revenue (ttm) | 29.80M |
| Net Income (ttm) | 5.43M |
| Shares Out | 11.31M |
| EPS (ttm) | 0.08 |
| PE Ratio | 260.24 |
| Forward PE | 31.06 |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 44,359 |
| Open | 20.66 |
| Previous Close | 20.89 |
| Day's Range | 20.66 - 21.63 |
| 52-Week Range | 19.40 - 44.50 |
| Beta | 0.81 |
| Analysts | Buy |
| Price Target | 62.50 (+192.9%) |
| Earnings Date | n/a |
About XOMA
XOMA Corporation, a biotechnology royalty aggregator, engages in helping biotech companies for improving human health. The company acquires the potential future economics associated with pre-commercial therapeutic candidates that have been licensed to pharmaceutical or biotechnology companies. It acquires the future economics, the seller receives non-dilutive, non-recourse funding they can use to advance internal drug candidate or for general corporate purposes. The company has a portfolio with approximately 70 assets. XOMA Corporation was inco...
Financial Performance
Financial StatementsAnalyst Forecast
According to 3 analysts, the average rating for XOMA stock is "Buy." The 12-month stock price forecast is 62.50, which is an increase of 192.88% from the latest price.
News
XOMA Declares Quarterly Preferred Stock Dividends
EMERYVILLE, Calif., Dec. 23, 2021 (GLOBE NEWSWIRE) -- XOMA Corporation (Nasdaq: XOMA) (“XOMA” or the “Company”) today announced its Board of Directors has authorized the following cash dividends to hold...
XOMA to Present at Upcoming Investor Conferences
EMERYVILLE, Calif., Dec. 21, 2021 (GLOBE NEWSWIRE) -- XOMA Corporation (Nasdaq: XOMA), a biotechnology royalty aggregator playing a distinctive role in helping companies achieve their goal of improving ...
XOMA Announces Evolution of Company Leadership and Succession Planning
Chief Executive Officer Jim Neal appointed as Chairman; Former Chairman W. Denman Van Ness to remain Lead Independent Director
Xoma (XOMA) Reports Q3 Loss, Misses Revenue Estimates
Xoma (XOMA) delivered earnings and revenue surprises of -466.67% and -85.22%, respectively, for the quarter ended September 2021. Do the numbers hold clues to what lies ahead for the stock?
XOMA Earns $35 Million Milestone Payment as Anti-TGFβ Antibody Enters Phase 3 Clinical Study in Metastatic Pancreatic...
EMERYVILLE, Calif., Nov. 04, 2021 (GLOBE NEWSWIRE) -- XOMA Corporation (Nasdaq: XOMA) announced today NIS793, an anti-TGFβ monoclonal antibody licensed from the Company, has advanced to the Phase 3 deve...
XOMA Reports Third Quarter 2021 Financial Results and Highlights Recent Operational Events
Added eight assets to its portfolio of potential milestone and royalty assets in 2021
Will Xoma (XOMA) Report Negative Q3 Earnings? What You Should Know
Xoma (XOMA) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Strength Seen in Xoma (XOMA): Can Its 11.2% Jump Turn into More Strength?
Xoma (XOMA) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might not help the stock continue moving higher in the near term.
XOMA to Present at the 2021 Cantor Fitzgerald Virtual Global Healthcare Conference
EMERYVILLE, Calif., Sept. 22, 2021 (GLOBE NEWSWIRE) -- XOMA Corporation (NASDAQ: XOMA)'s Chief Executive Officer, Jim Neal, will present at the 2021 Cantor Fitzgerald Virtual Global Healthcare Conferenc...
XOMA to Present at H.C. Wainwright 23rd Annual Global Investment Conference
EMERYVILLE, Calif., Sept. 13, 2021 (GLOBE NEWSWIRE) -- XOMA Corporation (NASDAQ: XOMA) announced today its Chief Executive Officer, Jim Neal, will present at the H.C. Wainwright 23rd Annual Global Inves...
XOMA Announces Heather L. Franklin Joins its Board of Directors
EMERYVILLE, Calif., Aug. 10, 2021 (GLOBE NEWSWIRE) -- XOMA Corporation (NASDAQ: XOMA) announced today Heather L. Franklin, President and Chief Executive Officer of Blaze Bioscience, Inc., has joined the...
Recap: XOMA Q2 Earnings
Shares of XOMA (NASDAQ:XOMA) were flat after the company reported Q2 results. Quarterly Results Earnings per share increased 12.12% over the past year to ($0.29), which beat the estimate of ($0.35).
Xoma (XOMA) Reports Q2 Loss, Misses Revenue Estimates
Xoma (XOMA) delivered earnings and revenue surprises of 24.39% and -56.89%, respectively, for the quarter ended June 2021. Do the numbers hold clues to what lies ahead for the stock?
XOMA Reports Second Quarter 2021 Financial Results and Highlights Recent Operational Events
Added six assets to its portfolio of potential milestone and royalty assets in 2021
Earnings Preview: Xoma (XOMA) Q2 Earnings Expected to Decline
Xoma (XOMA) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
U.S. Food and Drug Administration has Granted Orphan Drug Designation to XOMA's Licensed anti-TGFβ Asset NIS793
EMERYVILLE, Calif., July 28, 2021 (GLOBE NEWSWIRE) -- XOMA Corporation (NASDAQ: XOMA), announced today NIS793 in combination with standard of care chemotherapy has been granted Orphan Drug Designation i...
XOMA Buys Royalty, Milestone Interest In Checkmate's Vidutolimod From Kuros Biosciences
XOMA Corporation (NASDAQ: XOMA) has acquired the royalty interest position Kuros Biosciences holds in Checkmate Pharmaceuticals Inc's (NASDAQ: CMPI) vidutolimod (CMP-001), for $7.0 million upfront plus ...
Kuros to receive $7 million up front and potentially $166.5 million in future revenues under a royalty purchase agree...
Ad hoc announcement pursuant to Article 53 of the SIX listing rules Ad hoc announcement pursuant to Article 53 of the SIX listing rules
XOMA Acquires Royalty and Milestone Interest in Checkmate's Vidutolimod (CMP-001) from Kuros Biosciences
EMERYVILLE, Calif., July 15, 2021 (GLOBE NEWSWIRE) -- XOMA Corporation (NASDAQ: XOMA), announced today it has acquired the royalty interest position Kuros Biosciences holds in Checkmate Pharmaceuticals'...
XOMA Licensees to Present Significant Clinical Data at 2021 ASCO Annual Meeting
EMERYVILLE, Calif., May 21, 2021 (GLOBE NEWSWIRE) -- XOMA Corporation (Nasdaq: XOMA) recently learned its licensees are presenting at the upcoming 2021 American Society of Clinical Oncology (ASCO) Annua...
Xoma (XOMA) Reports Q1 Loss, Misses Revenue Estimates
Xoma (XOMA) delivered earnings and revenue surprises of -366.67% and -69.39%, respectively, for the quarter ended March 2021. Do the numbers hold clues to what lies ahead for the stock?
XOMA Reports First Quarter 2021 Financial Results and Highlights Recent Operational Events
XOMA's portfolio of potential milestone and royalty assets now has greater than 70 drug candidates. Company ended the first quarter of 2021 with $67.8 million in cash. The April 2021 $40 million Series...
XOMA Earns Milestone for First Patient Dosed in Phase 3 Development Program
EMERYVILLE, Calif., May 03, 2021 (GLOBE NEWSWIRE) -- XOMA Corporation (Nasdaq: XOMA) (“XOMA” or the “Company”) today announced it has earned a $0.5 million milestone from Janssen Biotech, Inc. (Janssen)...
XOMA's Royalty Portfolio Grows with Addition of Three Royalty Assets
EMERYVILLE, Calif., April 15, 2021 (GLOBE NEWSWIRE) -- XOMA Corporation (Nasdaq: XOMA) today announced its portfolio of potential future milestone and royalty assets has increased with the addition of t...
XOMA Announces Closing of Depositary Shares Offering and Exercise of Underwriters' Option
Raised aggregate gross proceeds of $40 million